Background: Increasing evidence from clinical trials indicates that carvedilol, an antagonist of a1-and h-adrenergic receptors (ARs), provides an effective treatment for chronic heart failure, whereas nonselective a1-AR blockade has an adverse outcome in this disease. It is, however, not clear whether carvedilol exhibits a subtype-dependent impact on three distinct a1-adrenergic receptors (a1-ARs). Methods and results: We determined binding properties of human ARs for carvedilol using HEK293 human embryonic kidney cells expressing a single AR subtype. Our results showed that the affinities of a1D-AR and a1B-AR for carvedilol are higher than that of the h1-AR subtype, a major target in heart failure treatment. The affinity rank order and pKi values of ARs for carvedilol were as follows: a1D-AR (8.9) > a1B-AR (8.6) > 1-AR (8.4) > h2-AR (8.0) > a1A-AR (7.9)Ha2C-AR (5.9) > a2B-AR (5.5) > a2A-AR (5.3). Furthermore, temporal kinetics of intracellular calcium signaling mediated via a1D-and a1B-ARs, but not via a1A-AR ( P < 0.01), showed oscillatory patterns with frequencies ranging from 0.3 to 3 per minute in human smooth muscle and HEK293 cells, which were inhibited by the therapeutic concentrations of carvedilol (10 nM) in a subtype-dependent manner. When oscillatory a1B-AR and non-oscillatory a1A-AR were coexpressed and heteromer receptors were detected with bioluminescence resonance energy transfer and co-immunoprecipitation, carvedilol suppressed only oscillatory component of global cytosolic free calcium change. Conclusions: These results indicate that in addition to hARs, receptor inhibition by carvedilol is directed to a1-ARs, preferably to a1D-and a1B-AR-mediated signaling events, including intracellular calcium oscillations in vascular smooth muscle.
Introduction
The increased sympathetic activity in chronic heart failure (CHF) is a compensatory adaptation to the initial disease stage that eventually damages the myocardium and vascular smooth muscle via stimulation of adrenergic receptors (ARs) and other neurohormonal and inflammatory signaling pathways [1] . The ARs consist of three distinct subclasses, namely, h-(h1, 2, and 3), a1-(a1A, 1B, and 1D), and a2-(a2A, 2B, and 2C) ARs [2, 3] . Several randomized clinical studies on CHF using subtype nonselective a1-adrenergic blockers, such as prazosin and doxazosin, failed to show efficacy compared to placebo or low-dose diuretics [4, 5] . Because both prazosin and doxazosin were shown to have proapoptotic properties on cardiac myocytes [6] , the therapeutic efficacy of blocking a1-ARs without the apoptotic effect has not been determined.
Conversely, treatment with carvedilol, a blocker of both hand a1-ARs with antioxidant effects, was significantly beneficial for CHF in several randomized clinical trials [7] [8] [9] [10] . Especially, a recently completed Carvedilol or Metoprolol European Trial (COMET) study, which was the first mortality study comparing two h blocking agents in patients with CHF, showed a significant improvement in survival rate in the carvedilol arm when compared to metoprolol, a h1-selective blocker [11] .
Although efficacy of carvedilol might be mainly attributable to its h-blocking effect [12, 13] , it has not been conclusively demonstrated whether the a1-AR blockade by carvedilol could have an additional benefit for CHF. Our focus in this study is to evaluate the subtype-specific inhibitory potencies of carvedilol against recombinant human ARs to clarify the preferential receptor subtypes for this drug. Specifically, emphasis is on the subtype selectivity of carvedilol relative to the a1-ARs. The three a1-AR subtypes, which couple to Gq type of G protein and the phospholipase C pathway, have different tissue and subcellular distributions, intracellular signaling cascades, and transcriptional profiles [14] . In arterial smooth muscle cells, these subtypes are frequently co-expressed and formation of homo-and hetero-oligomer a1-ARs is proposed [15 -17] . Our results revealed that a1D-and a1B-AR-dependent intracellular calcium signaling, which causes oscillatory changes in the intracellular calcium concentration ([Ca 2 + ] i ), is more susceptible to inhibition by carvedilol than the calcium signaling caused by the a1A-AR. Therefore, a1-ARs show subtypedependent sensitivity to carvedilol.
Experimental procedures

Materials
cDNAs for human h1-, h2-, a2A-, a2B-, and a2C-ARs were kind gifts from Dr. Robert J. Lefkowitz (Duke university). The cDNAs for h1-and h2-ARs that have an aminoterminal epitope tag for hemagglutinin protein were kindly provided by Dr. Hitoshi Kurose (Kyushu university) [18] . Characterization of cDNAs for human a1A-, a1B-, and a1D-ARs was described previously [19] . Carvedilol and KMD-3213 dihydrobromide were kindly provided by Daiichi Pharmaceutical (Tokyo, Japan) and Kissei Pharmaceutical (Matsumoto, Japan), respectively.
Expression constructs
Receptor cDNAs were subcloned into a mammalian expression vector, pcDNA1.3 (Invitrogen, Carlsbad, CA), at XhoI/KpnI (a1A-, a1B-, a1D-, a2A-, a2B-, and a2C-ARs) or at EcoRI/BamHI (h1-and h2-ARs) sites.
Cell culture and transfection
HEK293 human embryonic kidney cells were cultured in Dulbecco's modified Eagle's medium containing 10% heatinactivated fetal bovine serum, 100 U/ml penicillin, and 100 Ag/ml streptomycin. Human aortic smooth muscle cells (AoSM cells) were cultured according to the supplier's instruction (Cambrex, East Rutherford, NJ). The expression constructs (4.5 Ag DNA) were transfected into the cells grown in a 10-cm tissue culture dish by cationic lipid method using Lipofectamine Plus (Invitrogen). To obtain stable cell lines expressing each a1-AR, transfected cells were dispersed at 5 Â 10 5 cells/10 cm tissue culture dish, and Zeocin (0.5 mg/ ml) was included in the culture medium. Cloned stable cell lines were maintained in culture medium containing 0.2 mg/ ml Zeocin.
Membrane preparation and binding study
Cellular membrane fraction was prepared as described [20] Binding studies were performed as described previously [20] [21] [22] [23] [24] , binding studies of a2-ARs were performed in buffer B containing 140 mM NaCl and 100 AM Gpp(NH)p [21] . Specific radioligand binding was determined from the difference between counts in the presence or absence of 10 AM phentolamine (a1-and a2-ARs) or of 10 AM propranolol (h-ARs).
Measurement of intracellular calcium transients
HEK 293 cells stably expressing a1-ARs were tested for their ability to mobilize calcium using a fluorescent intracellular calcium assay kit (Molecular Devices, Sunnyvale, CA) and a fluorescence-imaging plate reader (FLIPR) system (Molecular Devices) according to the manufacturer's instructions. For dye loading cells in 100 Al Hank's/HEPES buffer (145 mM NaCl, 5 mM KCl, 0.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, pH 7.4) containing FLIPR calcium assay reagents were incubated for 1 h at 37 jC in black 96-well Viewplates (Polyfiltronics, Rockland, ME). Basal [Ca 2 + ] i conditions were monitored for 10 s before adding 50 Al of the agonist with an integrated 96-well pipetter. Fluorescence was measured from all 96 wells simultaneously using a charge-coupled device camera. Concentration-response curves were calculated as percentage of maximum response (E max ) induced by 10 AM phenylephrine. Agonist potency was expressed as pD 2 ( À log EC 50 ) value.
Single-cell [Ca 2 + ] i measurements were performed as described previously [25] . The wild-type HEK293 cells ] i change when stimulated with 10 AM phenylephrine (data not shown).
Measurement of biological resonance energy transfer
The cDNAs for the a1-ARs were connected in-frame with either yellow fluorescent protein (YFP) or Renilla luciferase (Rluc) gene to detect receptor-receptor interactions. The native stop codons of a1-ARs were changed to KpnI restriction enzyme site and genes for a variant YFP, ''Venus'' (F64L/M153T/V163A/S175G) [26] , and for Rluc with optimized codons for mammalian expression (Promega) were connected, resulting in two amino acid insertions of glycine and asparagine between the receptor and YFP or luciferase. All fusion constructs were sequenced and transferred to pcDNA3.1 (Invitrogen). The additions of amino-or carboxy-terminal tags to the a1-ARs had no significant effect on their binding and intracellular signalings [27] .
For biological resonance energy transfer (BRET) assays, transfected cells growing on a 10-cm culture dish were collected in PBS containing 1 mM EDTA and suspended in Hank's/HEPES buffer at 1 Â 10 6 /ml. After addition of coelenterazine h (Promega) at a final concentration of 5 AM, luminescence was detected with a fluorescence spectrophotometer (F-2500, Hitachi, Tokyo, Japan). The BRET signal was determined by calculating the ratio of the light emitted by the receptor-YFP at 535 nm to the light emitted by the receptor-Rluc at 480 nm. Background signal determined prior to the addition of coelenterazine h was always less than 1% of measured values and was subtracted.
Immunoprecipitation and Western blot analysis
The FLAG epitope was inserted between the initial methionine residue and the second amino acids of the a1-ARs by PCR. The 5V-primer sequence contained 6 bases of XhoI site, optimized translation sequence, 3 bases for methionine, 24 bases encoding the FLAG-peptide sequence, and 21 bases encoding 7 amino acids next to initiator methionine. Immunoprecipitation experiments were performed as described previously [25] , using anti-FLAG M2 antibody (Kodak, Rochester, NY) and anti-GFP antibody (MBL, Nagoya, Japan) at a concentration of 4 Ag/ml. For Western blot detection, monoclonal anti-FLAG M2 or anti-GFP antibodies were used at a dilution of 1:2000 and anti-extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and antiphospho-ERK1/2 antibodies (New England Biolabs) at a dilution of 1:1000. For secondary antibody, peroxidaseconjugated anti-mouse and anti-rabbit antibodies were diluted to 1:5000, and signals were visualized with enhanced chemiluminescence ECL (Amersham Biosciences).
Calculations
All values in the text are reported as mean F S.D. Significant differences, with P < 0.05 were determined by one-way ANOVA with Newman -Keuls multiple comparison test. Concentration -response relationships were fitted to a fourparameter logistic equation using a nonlinear curve-fitting program, which derives the EC 50 and Hill's values (Igor, WaveMetrics, Lake Oswego, OR). Calcium recordings were done in 10 -50 cells simultaneously, and each experiment was repeated three or more times to ensure the reproducibility of the findings. Table 1 [20 -23,28] . In competition binding experiments using membrane preparations from cells expressing each a1-AR, carvedilol was moderately selective for the a1B-and a1D-AR subtypes compared to the a1A-AR (Fig. 1A) . Thus, a tenfold difference was detected in the K i values between the a1D-and a1A-ARs (1.2 and 12 nM, respectively, Fig. 1 and Table 1 ). Notably, the affinities of a1B-and a1D-ARs for carvedilol were higher than any other 
Results
Affinities of human adrenergic receptors for carvedilol
Membranes from cells stably expressing a1-ARs and from transient transfectants expressing h-and a2-ARs were incubated with the corresponding radioligands in the presence or absence of antagonists as described in experimental procedures. B max and K d values were obtained from saturation binding curves and ÀpK i from competition binding experiments using carvedilol as an antagonist. The results were expressed as mean F S.D. from three to five experiments performed in duplicate.
ARs including h1-AR and h2-AR (Fig. 1B and Table 1 ). In contrast, a2-ARs showed weak binding to carvedilol with K i values in the micromolar range (Fig. 1C) .
Inhibition of a1-AR-mediated intracellular responses by carvedilol
The effects of high affinity binding of carvedilol to a1D-and a1B-AR subtypes were further examined by stimulating cells in the presence and absence of therapeutic concentrations of carvedilol (1 - ] i were shifted toward the right in the presence of carvedilol or phentolamine, keeping same maximum amplitudes ( Fig. 2A and B) . The calculated pA 2 values of carvedilol upon norepinephrine stimulation were 9.0, 10, and 10.2 for a1A-, a1B-, and a1D-ARs, respectively (Table 2) . Therefore, carvedilol is a competitive inhibitor with graded inhibitory potencies against three a1-ARs. When expressed in HEK cells, each a1-AR tagged with GFP shows specific patterns of cellular localization, as seen in Fig. 2C ; a1A-AR-GFP localized at both cell surface and intracellular part, while a1B-AR-GFP and a1D-AR-GFP were seen mostly at cell surface and at intracellular part, respectively. In spite of the distinct cellular localizations, activities of all a1-ARs were effectively controlled by carvedilol.
Single-cell calcium responses of a1-ARs
We next searched for an intracellular signaling pathway in AoSM cells, which could show specificity among 125 I]HEAT for a1A-AR, a1B-AR, and a1-AR were 256 F 20 (n = 3), 138 F 8 (n = 3), and 271 F 47 (n = 3) fmol/mg protein, respectively, while no specific binding sites of [
3 H]RX821002 were detected in these transfected cells.
In fura-2 loaded AoSM cells expressing a1A-AR, a submaximal concentration of 10 AM phenylephrine evoked a [Ca 2 + ] i increase of spike and plateau pattern (Fig. 3A) . In contrast, oscillatory patterns of [Ca ] i between oscillations (Fig. 3A) . The differences in the [Ca ] i response patterns among the a1-ARs were well preserved in HEK293 cells separately transfected with each a1-AR subtype (Fig. 3B) . Therefore, distinct oscillatory and non-oscillatory [Ca with 10 AM phentolamine, while ATP (100 AM)-induced calcium responses were not affected ( Fig. 3C and D) .
The effect of carvedilol on the subtype-dependent single-cell calcium responses of a1-ARs
We next examined an effect of carvedilol treatment on the single-cell calcium response patterns. The peak [Ca 2 + ] i amplitudes induced by 10 AM phenylephrine gradually decreased with increasing carvedilol concentrations used in all cell types (Fig. 4A) . In a1B-and a1D-AR expressing cells, spiking frequencies, in addition to the amplitudes, were significantly lowered by carvedilol (Fig. 4A) . These inhibitory effects were partially overcome by increasing agonist concentration to 100 AM in cells expressing a1B-AR (Fig. 4B ) and a1D-AR (not shown). In contrast to phenylephrine, a partial agonist at all of the human a1-ARs [29] , stimulation with submaximal concentration (10 AM) of norepinephrine, a full agonist for a1-ARs, resulted in high oscillatory frequencies in both a1B-and a1D-ARexpressing cells and [Ca ] i did not decrease to the basal resting level during oscillations (Fig. 4C) . Preincubation of the cells with 10 nM carvedilol and stimulation with norepinephrine resulted in a return to the large oscillatory pattern (Fig. 4C) ] i mobilization, the frequencies of which could be modulated by both agonist potencies and antagonist concentrations at single-cell level.
Inhibition of ERK1/2 phosphorylation by carvedilol
We further examined the effects of blocking each a1-AR on phenylephrine-induced ERK1/2 phosphorylation, which are related to cellular growth and hypertrophy. As shown in Fig. 5 , carvedilol (100 nM), as well as phentolamine (1 AM), significantly inhibited these ERK1/2 phosphorylations. When signals with phospho-ERK1/2 specific antibody were normalized by total ERK1/2 amount, ERK1/2 was phosphorylated more effectively in smooth muscle cells transiently expressing a1B-or a1D-ARs than in cells expressing a1A-AR (Fig. 5B) .
The effect of carvedilol on cells co-expressing a1-AR subtypes
Because different a1-AR subtypes are frequently coexpressed in the same vascular smooth muscle [14] , we examined subtype selectivity of carvedilol on cells coexpressing different a1-ARs. When YFP-tagged a1B-AR and Rluc-tagged receptors were co-expressed, significant (Fig. 6A) . These results suggested that when co-expressed, a1-ARs could form homomers and heterooligomers. The co-immunoprecipitation experiments confirmed interaction between a1B-AR and other subtypes (Fig. 6B) . In both BRET and co-immunoprecipitation experiments, a1B-AR interacted to YFP-tagged and Rluctagged a1-ARs with preference to a1D-AR and a1B-AR over a1A-AR (Fig. 6A and B) .
We then focused our analysis on the cells co-expressing a1A-AR and a1B-AR, which cause two distinct [Ca oscillation (Fig. 7B) . Thus, among the homo-and heterooligomeric receptors formed in the cells co-expressing a1A-AR and a1B-AR subtypes, carvedilol effectively inhibited the receptors responsible for the oscillatory component of complex [Ca 
Discussion
Recombinant expression of each AR subtype enabled us to delineate a series of inhibitory potencies of carvedilol in the adrenergic system. Thus, the binding affinities of carvedilol for a1D-and a1B-ARs were comparable to that for h1-AR and were more potent than those for h2-AR and a1A-AR subtypes. Several meta-analysis and COMET study for CHF showed consistent benefit of combined a1-and h-AR blockade by carvedilol [11, 30] . It was also reported that carvedilol lowered coronary sinus norepinephrine levels, an index of cardiac adrenergic activity, whereas metoprolol actually increased central venous norepinephrine levels [31] . Although the mechanism whereby carvedilol lowers norepinephrine levels needs to be further investigated, findings from a1D-AR knockout mice suggested that ablating the function of this subtype attenuates the elevation of plasma norepinephrine level during the development of hypertension accompanied with renal failure [32] . When bucindolol, a nonselective h-AR blocker with only weak a1-AR blocking activity, was used for CHF in h-Blocker Evaluation of Survival Trial, it increased the combined endpoints of death or heart failure hospitalization within the first 6 months and did not result in overall benefit [33] . Although patient populations and severity of the disease differ in each CHF trial, these results indicate that AR types, which are selected for a pharmacological intervention, could have a significant impact on the final outcome of CHF treatment.
Previous pharmacokinetics data suggested that 25 and 50 mg oral administration of carvedilol produced peak plasma levels of 150 and 300 nM, respectively, and about 95% of carvedilol was found to bind to plasma proteins [34] . These plasma concentrations indicate that blockade of a1-and hARs by carvedilol could occur in a linear range of the competition binding curve and that ligand binding to a2-ARs could be largely preserved. However, in examining ligand affinities using recombinant receptors and translating these results to efficacy estimation of agonist and antagonist in vivo, care should be taken for potential difference in cellular environment, which might influence receptor functions. In addition, there is species difference in relative affinities of carvedilol to a1-and h-ARs. By using vascular preparation from pithed rat, Ruffolo et al. [35] found that K B values of h-and a1-ARs for carvedilol were 0.9 and 11 nM, respectively. On the other hand, Bristow et al. [36] used membrane preparations from human ventricular myocardium for radioligand assay and found that K i values of h1-and a1-ARs for carvedilol were 4.5 and 8.1 nM, respectively. Thus, the ratios of h1-AR/a1-AR blocking activities of carvedilol are 12 and 1.7 for rat and human receptors, respectively. The reason for lower affinity rank order of a1-AR than the h1-AR in human heart is based on the fact that main cardiac a1-AR subtype has been reported to be the a1A-AR subtype, although the exact amount of each a1-AR protein has not been examined [37] . Therefore, binding affinities calculated in our study using recombinant human ARs should provide basic knowledge for understanding affinities of native ARs against carvedilol.
The a1-ARs in the peripheral vasculature play a major role in positively regulating arterial vascular tone [15] . Gene targeting for each of the a1-AR subtype further revealed that deletion of one subtype gene was directly correlated to the attenuated pressor response to an a1-AR agonist administered intravenously [38] [39] [40] . Therefore, there was minimal functional redundancy among the three vascular a1-AR subtypes and blocking a specific fraction of a1-AR had direct impact on the regulation of systemic blood pressure.
Recent clinical studies, however, indicate that efficacy of carvedilol during CHF treatment might not belong to its ability to reduce peripheral vascular resistance. Chronic administration of carvedilol to CHF patients did not increase calf vascular conductance and did not attenuate vasoconstrictor response of forearm vasculature to adrenergic stimuli [41, 42] . From these results, biological process that is suppressed by carvedilol is not likely to be hemodynamic change in microvasulature, but might be related to metabolic or hypertrophic signaling to arterial smooth muscle cells via vascular a1-ARs [43] . In fact, carvedilol effectively attenuated phosphorylation of ERK1/2. Furthermore, deletion of mouse a1B-AR gene resulted in a beneficial effect for preventing remodeling of peripheral vessels and cardiac muscle induced by continuous infusion of phenylephrine at subpressor doses [44] .
Native arterial smooth muscle cell frequently co-expresses distinct a1-AR subtypes [43, 45] , in which heteromeric receptor can be composed of different a1-AR subtypes [16, 17] . Receptor heteromerization between a1A-and a1B-ARs increased total receptor binding sites and internalized a1B-AR in response to stimulation of an a1A-AR-selective agonist, oxymetazoline [16, 17] . Analysis of the heteromerspecific character at single-cell level can be confounded by the concomitant presence of homomeric receptors. We found that in a cell co-expressing non-oscillatory a1A-AR and oscillatory a1B-AR subtypes to a similar extent, a pattern of global intracellular [Ca In conclusion, the a1D-and a1B-ARs show high affinities for carvedilol, which are comparable to that of h1-AR. The oscillatory [Ca 2 + ] i responses by a1D-and a1B-ARs are distinct from the response induced by a1A-AR and are more susceptible to carvedilol. From the results of clinical studies, it was concluded that subtype-nonselective anti-a1-AR antagonist is not a first-line drug for the CHF treatment, while an effectiveness of a subtype-selective a1-blocker directed against a1D-and/or a1B-ARs in combination with h-blockade needs to be further addressed in clinical and basic research fields. Thus, obtaining knowledge of the cellular and molecular targets of an effective medication supported with clinical evidence could be valuable and efficient information in developing a better treatment strategy for patients with CHF.
